The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience☆☆This study was sponsored by Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Aventis Pharma, Bridgewater, New Jersey.
Abstract
Limited placebo-controlled data are available to assess the long-term fracture efficacy of bisphosphonates. In order to determine the effects of 5 years of risedronate treatment, we extended a 3-year, placebo-controlled vertebral fracture study in osteoporotic women for an additional 2 years; women who entered the extension study continued to receive 5 mg risedronate or placebo according to the original randomization, with maintenance of blinding. End points included vertebral and nonvertebral fracture assessments, bone mineral density measurements, and changes in biochemical markers of bone turnover. A total of 265 women (placebo, 130; 5 mg risedronate, 135) entered the study extension and 220 (83%) completed the additional 2 years. Fracture results observed in the study extension were consistent with those observed in the first 3 years. The risk of new vertebral fractures was significantly reduced with risedronate treatment in years 4 and 5 by 59% (95% confidence interval, 19 to 79%, P = 0.01) compared with a 49% reduction in the first 3 years. Rapid and significant decreases in markers of bone turnover observed in the first 3 years were similarly maintained in the next 2 years of treatment. Increases in spine and hip bone mineral density that occurred in the risedronate group during the first 3 years were maintained or increased with a further 2 years of treatment. The mean increase from baseline in lumbar spine BMD over 5 years was 9.3% (P < 0.001). This study demonstrate…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence of efficacy beyond 5 years is limited, whereas rare safety concerns such as ONJ and atypical femur fractures become more common beyond 5 years [67, 92].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [67]
In the citing paper
“Evidence of efficacy beyond 5 years is limited, whereas rare safety concerns such as ONJ and atypical femur fractures become more common beyond 5 years [67, 92].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [67]
Citations
Cites
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationChesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN
Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682
Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women1
Tonino, R. P., Meunier, P. J., Emkey, R., Rodriguez-Portales, J. A., Menkes, C.-J., Wasnich, R. D., Bone, H. G., Santora, A. C., Wu, M., Desai, R., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6777 · Cited by 335
Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women
Tonino, R. P. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.9.3109 · Cited by 188
Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis
Miller, P. D., Watts, N. B., Licata, A. A., Harris, S. T., Genant, H. K., Wasnich, R. D., Ross, P. D., Jackson, R. D., Hoseyni, M. S., Schoenfeld, S., et al. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00278-7 · Cited by 161
Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women
Heaney, R. P., Zizic, T. M., Fogelman, I., Olszynski, W. P., Geusens, P., Kasibhatla, C., Alsayed, N., Isaia, G., Davie, M. W. J., & Chesnut, C. H. (2002) · Osteoporosis International · doi:10.1007/s001980200061 · Cited by 78
Research works printed but not linked: 1
- Eastell, 2000, The effects of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis, J Bone Miner Res, 15, S229
Cited by
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
BackgroundShane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Epidemiology, etiology, and diagnosis of osteoporosis
Lane, N. E. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.08.047 · Cited by 1,293
Sambrook, P., & Cooper, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,165
Self-citation
Metadata
- Authors
- Sorensen, O. H., Crawford, G. M., Mulder, H., Hosking, D. J., Gennari, C., Mellstrom, D., Pack, S., Wenderoth, D., Cooper, C., & Reginster, J.-Y.
- Affiliations
- Nottingham City Hospital (GB)
- University of Siena (IT)
- Procter & Gamble (United Kingdom) (GB)
- University of Southampton (GB)
- University of Liège (BE)
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2003-02
- Volume
- 32
- Issue
- 2
- Pages
- 120-126
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2125721609
- Cited by
- 254
- References
- 12
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 10 · 2015: 7 · 2014: 4 · 2013: 13 · 2012: 10
- FWCI
- 30.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Bone (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- risedronate, bisphosphonates, osteoporosis, vertebral fractures, non-vertebral fractures, bone mineral density, bone turnover markers, long-term treatment efficacy, postmenopausal women, hip bone density, lumbar spine
- MeSH terms
- Aged, Aged, 80 and over, Female, Humans, Risk Factors, Etidronic Acid, Time, Bone Density, Osteoporosis, Postmenopausal, Confidence Intervals, Spinal Fractures, Statistics, Nonparametric
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience☆☆This study was sponsored by Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Aventis Pharma, Bridgewater, New Jersey. https://app.cochat.ai/papers/10.1016/s8756-3282(02)00946-8
- The paper
- Sorensen, O. H., Crawford, G. M., Mulder, H., Hosking, D. J., Gennari, C., Mellstrom, D., Pack, S., Wenderoth, D., Cooper, C., & Reginster, J.-Y. (2003). Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience☆☆This study was sponsored by Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Aventis Pharma, Bridgewater, New Jersey. Bone. https://doi.org/10.1016/s8756-3282(02)00946-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.